Onkológia 3/2013

Tyrosine kinase inhibitor sunitinib malate

Perorally administered tyrosine kinase inhibitor (TKI) sunitinib malate is nowadays indicated in the treatment of advanced and/or metastatic kidney cancer carcinoma, unresecable and/or metastatic gastrointestinal stromal tumour after the failure of imatinib treatment as a result of intolerance or resistance and progression unresecable or metastatic well-differentiated pancreatic neuroendocrine tumour. The majority of sunitinib treatment side effects (fatigue, diarrhoea, nausea, anorexia, hypertension, yellow skin discoloration, handand- foot syndrome, stomatitis) are manageable by the supportive care, sunitinib treatment interruption or sunitinib dose-reduction. Hypertension is considered to be a biomarker of sunitinib treatment efficiency in patients with metastatic kidney cancer.

Keywords: sunitinib, kidney cancer, gastrointestinal stromal tumour, pancreatic neuroendocrine tumour.